InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (14 ops.)
Insider track record
CEODisclosed buys
0
Disclosed sells
14
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Discover the detailed record of transactions filed by Posner Christopher, Chairman & CEO. Director active across 1 company, notably Cara Therapeutics, Inc.. Aggregated, 20 reports have been logged. Breakdown: 0 buy · 14 sells. Total volume traded: €342k. Activity tracked since 3 June 2021. The latest transaction was disclosed on 28 February 2025 (Cession). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations20 total
583 shares@ US$4.750.8% of flowCommon StockSEC:0001415889-25-006576:0
372 shares@ US$4.720.5% of flowCommon StockSEC:0001415889-25-003295:0
3,668 shares@ US$0.290.3% of flowCommon StockSEC:0001415889-24-026248:0
4,149 shares@ US$0.350.4% of flowCommon StockSEC:0001415889-24-020605:0
3,936 shares@ US$0.750.8% of flowCommon StockSEC:0001415889-24-012322:0
5,834 shares@ US$0.891.4% of flowCommon StockSEC:0001415889-24-006273:0
35,575 shares@ US$0.535.1% of flowCommon StockSEC:0001415889-24-003395:0
62,500 shares0Common StockSEC:0001415889-24-002513:0
3,796 shares@ US$1.221.3% of flowCommon StockSEC:0001209191-23-054332:0
4,307 shares@ US$3.073.5% of flowCommon StockSEC:0001209191-23-044636:0
3,869 shares@ US$4.404.5% of flowCommon StockSEC:0001209191-23-028247:0
5,987 shares@ US$9.7116.0% of flowCommon StockSEC:0001209191-23-016796:0
4,191 shares@ US$11.8013.1% of flowCommon StockSEC:0001209191-23-007170:0
14,470 shares@ US$11.1345.5% of flowCommon StockSEC:0001209191-22-057948:0
2,006 shares@ US$12.67100.0% of flowCommon StockSEC:0001209191-22-023237:0
39,000 shares0Common StockSEC:0001209191-22-013988:0
5,941 shares0Common StockSEC:0001209191-21-062593
5,941 shares0Common StockSEC:0001209191-21-062593:0
7,200 shares0Common StockSEC:0001209191-21-038764:0
7,200 shares0Common StockSEC:0001209191-21-038764
20 of 20 declarations
About Posner Christopher
Christopher Posner is President and CEO of Cara Therapeutics, Inc. In this role, he oversees all operations of the company and ensures performance objectives are met. His expertise in the biopharmaceutical sector is essential for the development of Cara.
